Literature DB >> 18650966

A pharmacological analysis of the possible role of vasoactive mediators in compensatory coronary blood flow.

James R Parratt1, Agnes Végh.   

Abstract

BACKGROUND: Coronary blood flow in one (circumflex) branch of the left coronary artery increases when an adjacent (left anterior descending [LAD]) branch is occluded for periods of between 1 min and 25 min.
OBJECTIVE: To examine the possible role of the myocardial release of vasoactive substances in such 'compensatory blood flow' increase by the classical pharmacological approach of inhibition of synthesis, or blockade at the receptor level, of the most likely mediators.
METHODS: In pentobarbitone anesthetized, thoracotomized dogs, coronary blood flow changes were measured in both the LAD (using a Doppler flow probe) and the left circumflex (using an electromagnetic flow probe) coronary arteries.
RESULTS: The flow increase during 5 min occlusions of the LAD coronary artery was unaffected by blockade of adenosine receptors by 8-sulfophenyltheophylline, inhibition of prostanoid synthesis by sodium meclofenamate or celecoxib, blockade of bradykinin B(1) receptors by icatibant, inhibition of nitric oxide synthesis by N(omega)-nitro-L-arginine methyl ester (L-NAME), inhibition of guanylyl cyclase by methylene blue, or opening (using diazoxide) and closing (using glibenclamide or 5-hydroxydecanote) of ATP-dependent K(+) channels. Neither dual blockade with L-NAME and glibenclamide, or meclofenamate and 5-hydroxydecanote, nor triple blockade with L-NAME, glibenclamide and 8-sulfophenyltheophylline, modified the blood flow response. However, it was greatly reduced (60%) by metoprolol.
CONCLUSIONS: These results suggest that coronary vascular beta(1)-adrenoceptors are involved in 'compensatory' vasodilation, whereas bradykinin, nitric oxide, prostanoids and ATP-dependent K(+) channels are seemingly not required for this flow increase.

Entities:  

Keywords:  Coronary blood flow; Myocardial ischemia; Vasoactive substances

Year:  2008        PMID: 18650966      PMCID: PMC2435397     

Source DB:  PubMed          Journal:  Exp Clin Cardiol        ISSN: 1205-6626


  35 in total

Review 1.  Control of coronary blood flow by autacoids.

Authors:  E Bassenge
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

Review 2.  Coronary vascular adjustments to acute myocardial ischemia.

Authors:  T W Moir
Journal:  Arch Intern Med       Date:  1972-05

3.  Coronary artery occlusion in the intact unanesthetized dog: intercoronary reflexes.

Authors:  E E Joyce; D E Gregg
Journal:  Am J Physiol       Date:  1967-07

Review 4.  Eicosanoids and the coronary circulation.

Authors:  T Simmet; B A Peskar
Journal:  Rev Physiol Biochem Pharmacol       Date:  1986       Impact factor: 5.545

Review 5.  The role of adenosine in the regulation of coronary blood flow.

Authors:  R M Berne
Journal:  Circ Res       Date:  1980-12       Impact factor: 17.367

6.  Regional myocardial function during acute coronary artery occlusion and its modification by pharmacologic agents in the dog.

Authors:  P Theroux; D Franklin; J Ross; W S Kemper
Journal:  Circ Res       Date:  1974-12       Impact factor: 17.367

7.  Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta.

Authors:  W Martin; G M Villani; D Jothianandan; R F Furchgott
Journal:  J Pharmacol Exp Ther       Date:  1985-03       Impact factor: 4.030

8.  Coronary inflow and outflow responses to coronary artery occlusion.

Authors:  T E Driscol; R W Eckstein
Journal:  Circ Res       Date:  1967-05       Impact factor: 17.367

9.  Are prostaglandins involved in the regulation of coronary blood flow? A review of the evidence.

Authors:  J R Parratt; R J Marshall
Journal:  Acta Biol Med Ger       Date:  1978

10.  Delayed exercise-induced protection against arrhythmias in dogs--effect of celecoxib.

Authors:  Orsolya Nagy; Agnes Hajnal; James R Parratt; Agnes Végh
Journal:  Eur J Pharmacol       Date:  2004-09-19       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.